Sabato 20 Ottobre 2018 | 10:56

NEWS DALLA SEZIONE

Florence
Fashion: Wanda Ferragamo is dead

Fashion: Wanda Ferragamo is dead

 
Rome
Spread closes down on 301.6 points after hitting 340 (2)

Spread closes down on 301.6 points after hitting 340 (2...

 
Rome
New 'hostile act' by France, relations at risk-Salvini

New 'hostile act' by France, relations at risk-Salvini

 
Rome
Won't be made to look a liar or distracted - Di Maio

Won't be made to look a liar or distracted - Di Maio

 
Rome
Critical situation in migrant centres - watchdog

Critical situation in migrant centres - watchdog

 
Matera
Matera water emergency over

Matera water emergency over

 
Rome
Ball in Italy's court now - Moscovici

Ball in Italy's court now - Moscovici

 
Rome
Won't be made look a fool - Salvini

Won't be made look a fool - Salvini

 
Rome
Leonardo may have had a squint - study

Leonardo may have had a squint - study

 
Rome
Growth slowing, foreign investors cutting BTP exposure - BoI

Growth slowing, foreign investors cutting BTP exposure ...

 
ROMA
Uruguay: parlamento approva legge su diritti dei transgender

Uruguay: parlamento approva legge su diritti dei transg...

 
Gazzettaffari - Portale di annunci de La Gazzetta del Mezzogiorno

i più letti

Rome

Roche, Novartis CEOs risk trial for scorning drug (4)

Accused of share-rigging for denigrating Avastin

Roche, Novartis CEOs risk trial for scorning drug (4)

Rome, December 7 - The CEOs of Roche and Novartis risk trial in Italy for share-rigging over alleged denigratory campaign starting in 2011 against the eye-disease drug Avastin, prosecutors said Thursday. Roche's Maurizio De Cicco and Novartis's George Schrockn Fuchs received notification that a probe had ended, which is generally the prelude to an indictment request. The two managers are accused of conspiring to obstruct, via the diffusion of false news, the use of the very cheap Avastin in favour of a much dearer product, Lucentis. The two pharmaceutical giants were fined 180 million euros by Italian antitrust authorities for this affair. Rome prosecutors have based their case on the content of emails between De Cicco and Schrockn Fuchs. They are also relying on the results of a technical consultation which assessed the characteristics of the two products and their therapeutic efficacy. Both CEOs and their firms denied the charges, saying they had done nothing wrong. "We have nothing whatsoever to do with the charges," they said.

Lascia il tuo commento

Condividi le tue opinioni su

Caratteri rimanenti: 400